$Immuneering (IMRX.US)$ The news of the initial results of t...

News of good initial results in clinical trials has caused a sharp rise, but it is limited to pancreatic cancer and there are only five cases, so the frenzy cannot be denied.

It is said that cash will be maintained until the second half of 2025, but since it is a company with zero revenue, there is a high possibility of a significant decline.

It is said that the evaluation data of the current clinical trials will be released by the end of the year.

It is likely that a significant increase will occur there and it will be the last big rise.